Steffen Weikert

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

Brian I. Rini, Arnulf Stenzl, Romauld Zdrojowy et al. · The Lancet Oncology · 2016 · 211 citations

Sunitinib Versus Sunitinib, Urology, Genitourinary Cancer +8

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma

Manfred Johannsen, Gianluca Spitaleri, Giuseppe Curigliano et al. · European Journal of Cancer · 2010 · 179 citations

Urology, Cancer Immunosurveillance, Genitourinary Cancer +7

Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas

Steffen Weikert, Frank Christoph, Jens Köllermann et al. · International Journal of Molecular Medicine · 2005 · 151 citations

Bladder Carcinomas, Cancer Biology, Tumor Biology +18

miRNA Profiling Identifies Candidate miRNAs for Bladder Cancer Diagnosis and Clinical Outcome

Nadine Ratert, Hellmuth‐Alexander Meyer, Monika Jung et al. · Journal of Molecular Diagnostics · 2013 · 143 citations

Urology, Oncology, Genitourinary Cancer +11

Body Size and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition

Tobias Pischon, Heiner Boeing, Steffen Weikert et al. · Cancer Epidemiology Biomarkers & Prevention · 2008 · 129 citations